On Monday, Shares of Anthem Inc (NYSE:ANTM), added 3.68% and closed at $138.60 in the last trading session. The last trading range of the stock ranges between $132.65 and $138.75. Boehringer Ingelheim Pharmaceuticals, Inc., Anthem, Inc. and HealthCore Inc. recently declared the final results from the first phase of a three phase, large-scale research partnershipto generate real-world evidence to assist inform the development of new medicines, guidelines and interventions. The study assessed oral anticoagulant (OAC) treatment and persistence in NVAF patients, and showed a discrepancy between treatment guidelines and clinical practice at diagnosis and throughout the treatment journey. NVAF is an important risk factor for stroke and clinical trial data has shown that OAC therapy substantially reduces stroke risk in NVAF patients. The findings were presented at the American Heart Association Scientific Sessions 2016 in New Orleans.
“As the first joint research project of its kind, we believe these data have the potential to assist us identify treatment gaps in NVAF patient care,” said Mark Cziraky, vice president of research of HealthCore, Inc., the independent outcomes research partner of Anthem. “In the next phases, we will focus our research on why these gaps exist, what can be done to bridge these gaps and how this may assist improve patient outcomes.”
Iconix Brand Group Inc (NASDAQ:ICON), jumped 1.80% and closed at $9.64 in the last trading session. The last trading range of the stock ranges between $9.52 and $9.98. The company’s Market capitalization is $573.88 million with the total Outstanding Shares of 56.13 million. Iconix Brand Group, Inc. (ICON) (“Iconix” or the “Company”) recently stated its financial results for the third quarter and nine months ended September 30, 2016.
John Haugh, CEO of Iconix commented, “I am happy to report that Iconix delivered another solid quarter. Performance across the brands was mixed, but with our balanced portfolio of brands and the Company’s attractive margins, we were able to achieve stable revenue, raised profits and healthy free cash flow. We look forward to sharing details about our vision and our growth plan at our forthcoming shareholder day next Tuesday, November 15th.”
Third Quarter 2016 Financial Results
Licensing Revenue: For the third quarter of 2016, licensing revenue was about $90.9 million, flat to the prior year quarter. Revenue in the prior year’s third quarter included about $1.2 million of licensing revenue from the Badgley Mischka brand, for which there was no comparable revenue in the third quarter of 2016, because of its sale in the first quarter of 2016. The third quarter of 2016 benefitted from a $1.6 million favorable impact from foreign currency exchange rates mainly related to the Yen.